Mechanisms of regulatory T cell-mediated recovery from severe influenza A virus infection
调节性 T 细胞介导的严重甲型流感病毒感染恢复机制
基本信息
- 批准号:10356911
- 负责人:
- 金额:$ 50.13万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-03-01 至 2025-02-28
- 项目状态:未结题
- 来源:
- 关键词:AREG geneAcuteAcute Lung InjuryAcute Respiratory Distress SyndromeAdaptor Signaling ProteinAlveolarAmphiregulinAntiviral AgentsAntiviral TherapyBackBronchoalveolar LavageCaringCase-Control StudiesCellsCessation of lifeClinical ResearchControl LocusCritical IllnessCytosineDNADNA BindingDNA MaintenanceDNA MethylationDNA Modification MethylasesDataDevelopmentDrug TargetingEpigenetic ProcessEpithelialFOXP3 geneFlow CytometryGene Expression ProfileGenerationsGenetic TranscriptionGrowth FactorGuanineHumanInfectionInflammationInfluenzaInfluenza A virusIntensive Care UnitsLinkLungMediatingMorbidity - disease rateMusPathway interactionsPatientsPhasePhysiologicalPlayPneumoniaProtein IsoformsProteinsPublishingPulmonary InflammationReagentRecoveryRecovery of FunctionRegulator GenesRegulatory ElementRegulatory T-LymphocyteResearch InfrastructureResolutionRiskRoleSupportive careSystemT-Lymphocyte SubsetsTechnical ExpertiseTestingTherapeuticTimeTissuesTranslatingViralViral PneumoniaVirus DiseasesWorkalveolar epitheliumcell typecomputational platformdimensional analysisepithelial repairexperimental studygene repairgenomic locusinfluenza infectioninnovationlung injurylung repairmethylation patternmortalitymouse modelnovelnovel therapeuticsprogramsrecruitrepair functionrepairedrespiratoryseasonal influenza
项目摘要
PROJECT SUMMARY/ABSTRACT
Seasonal influenza is associated with up to 650,000 respiratory deaths per year worldwide. Influenza A virus
injures the lung to cause the acute respiratory distress syndrome (ARDS). Influenza A virus-induced ARDS
carries a mortality rate approaching 40% despite advances in anti-viral therapies and supportive care, with most
patients succumbing to intensive care unit (ICU) complications as they recover from the initial infection. In mice,
dysregulated repair leads to widespread and persistent alveolar epithelial abnormalities following severe
influenza A. We reason that activation of repair pathways during recovery from severe influenza will shorten the
duration of time that patients require the ICU, thus mitigating the ICU’s attendant morbidity and mortality.
CD4+Foxp3+ regulatory T (Treg) cells are required to coordinate resolution of lung inflammation and repair of
lung damage in mouse models. These cells appear in the alveolar spaces of patients with ARDS and display
epigenetic and transcriptional profiles predicted by murine experiments. In the injured lung, Treg cells exert
myriad pro-recovery functions, including generation of pro-epithelial molecules such as amphiregulin, the loss of
which worsens influenza A-induced acute lung injury in mice. Within Treg cells, the DNA methylation pattern at
specific genomic loci controls their identity and suppressive function. The epigenetic regulator protein Uhrf1 plays
an essential role in maintaining cell type-specific DNA methylation signatures. The necessity of Uhrf1 in
maintaining Treg cell identity and pro-repair function during the recovery phase of influenza A remains unknown.
Likewise, the necessity of amphiregulin in inducing healthy epithelial repair during the recovery phase is also
undefined. We hypothesize that Treg cells require Uhrf1 to maintain their pro-repair function and
amphiregulin to induce epithelial repair during recovery from severe influenza A virus infection. We
propose three Specific Aims, which use innovative approaches to test our hypothesis, including cutting-edge
murine systems, novel computational platforms, and a human case-control study that will translate our findings
to the bedside. Aim 1 will determine whether Uhrf1 is necessary to maintain Treg cell transcriptional programs
and pro-repair function during recovery from influenza A. Aim 2 will ascertain the necessity of Treg cell-generated
amphiregulin in promoting repair during recovery from influenza A-induced lung injury. Aim 3 will determine
whether transcriptional and epigenetic signatures in alveolar Treg cells are associated with 30-day mortality in
selected patients with severe viral pneumonia. Our proposal will establish causal evidence linking drug-
targetable mechanisms to detailed physiologic readouts. Elucidating these causal links will inform the
development of pro-recovery therapeutic approaches for severe influenza and other causes of ARDS.
项目摘要/摘要
全球每年有多达65万人死于季节性流感。甲型流感病毒
损伤肺部导致急性呼吸窘迫综合征(ARDS)。甲型流感病毒致急性呼吸窘迫综合征
尽管在抗病毒治疗和支持性护理方面取得了进展,但死亡率接近40%,大多数
患者在从最初的感染中恢复时会出现重症监护病房(ICU)并发症。在老鼠身上,
失调性修复导致广泛而持久的肺泡上皮异常
甲型流感我们的理由是,在严重流感康复期间激活修复通路将缩短
患者需要ICU的持续时间,从而降低ICU的随之而来的发病率和死亡率。
CD4+Foxp3+调节性T(Treg)细胞需要协调肺部炎症的消退和修复
小鼠模型的肺损伤。这些细胞出现在ARDS患者的肺泡间隙并显示
由小鼠实验预测的表观遗传学和转录图谱。在受损的肺中,Treg细胞施加
无数的促恢复功能,包括产生亲上皮分子,如两性调节素,丢失
这会加重甲型流感引起的小鼠急性肺损伤。在Treg细胞内,DNA甲基化模式在
特定的基因组基因座控制着它们的身份和抑制功能。表观遗传调节蛋白uhrf1发挥作用
在维持细胞类型特定的DNA甲基化特征方面起着至关重要的作用。UHRF1在中国的必要性
在甲型流感恢复期维持Treg细胞的特性和促进修复的功能仍不清楚。
同样,在恢复期,两亲调节素在诱导健康的上皮修复中的必要性也是必要的
未定义。我们假设Treg细胞需要uhrf1来维持其促修复功能,并且
在严重甲型流感病毒感染的康复过程中,双调节素能诱导上皮修复。我们
提出三个具体目标,它们使用创新的方法来验证我们的假设,包括尖端
小鼠系统,新的计算平台,以及将翻译我们的发现的人类病例对照研究
到床边去。目标1将确定uhrf1是否是维持Treg细胞转录程序所必需的
以及在甲型流感康复过程中的修复功能目标2将确定Treg细胞产生的必要性
双调蛋白在甲型流感所致肺损伤恢复过程中的促进修复作用。目标3将决定
肺泡Treg细胞的转录和表观遗传特征是否与30天死亡率有关
入选的重症病毒性肺炎患者。我们的提案将建立与毒品有关的因果证据-
有针对性的机制,以详细的生理读数。阐明这些因果联系将使
为严重流感和ARDS的其他原因开发促进康复的治疗方法。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Benjamin David Singer其他文献
Benjamin David Singer的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Benjamin David Singer', 18)}}的其他基金
Epigenetic modifiers of regulatory T cell function following viral pneumonia
病毒性肺炎后调节性 T 细胞功能的表观遗传修饰
- 批准号:
10209664 - 财政年份:2021
- 资助金额:
$ 50.13万 - 项目类别:
Project 4: Epigenetic modifiers of regulatory T cell function following viral pneumonia
项目 4:病毒性肺炎后调节性 T 细胞功能的表观遗传修饰
- 批准号:
10269677 - 财政年份:2021
- 资助金额:
$ 50.13万 - 项目类别:
Project 4: Epigenetic modifiers of regulatory T cell function following viral pneumonia
项目 4:病毒性肺炎后调节性 T 细胞功能的表观遗传修饰剂
- 批准号:
10696966 - 财政年份:2021
- 资助金额:
$ 50.13万 - 项目类别:
Mechanisms of regulatory T cell-mediated recovery from severe influenza A virus infection
调节性 T 细胞介导的严重甲型流感病毒感染恢复机制
- 批准号:
10116463 - 财政年份:2020
- 资助金额:
$ 50.13万 - 项目类别:
Mechanisms of regulatory T cell-mediated recovery from severe influenza A virus infection
调节性 T 细胞介导的严重甲型流感病毒感染恢复机制
- 批准号:
10586095 - 财政年份:2020
- 资助金额:
$ 50.13万 - 项目类别:
Regulatory T cell Uhrf1 and DNA methylation in repair of acute lung injury
调节性T细胞Uhrf1和DNA甲基化在急性肺损伤修复中的作用
- 批准号:
9118337 - 财政年份:2015
- 资助金额:
$ 50.13万 - 项目类别:
Epigenetic Regulation of Acute Lung Injury Resolution
急性肺损伤消退的表观遗传调控
- 批准号:
8725989 - 财政年份:2013
- 资助金额:
$ 50.13万 - 项目类别:
Epigenetic Regulation of Acute Lung Injury Resolution
急性肺损伤消退的表观遗传调控
- 批准号:
8590629 - 财政年份:2013
- 资助金额:
$ 50.13万 - 项目类别:
相似海外基金
Combinatorial cytokine-coated macrophages for targeted immunomodulation in acute lung injury
组合细胞因子包被的巨噬细胞用于急性肺损伤的靶向免疫调节
- 批准号:
10648387 - 财政年份:2023
- 资助金额:
$ 50.13万 - 项目类别:
Lung epithelial cell-derived C3 in acute lung injury
肺上皮细胞衍生的 C3 在急性肺损伤中的作用
- 批准号:
10720687 - 财政年份:2023
- 资助金额:
$ 50.13万 - 项目类别:
Examining the role of TRMT1 and tRNA methylation in acute lung injury and ARDS
检查 TRMT1 和 tRNA 甲基化在急性肺损伤和 ARDS 中的作用
- 批准号:
10719249 - 财政年份:2023
- 资助金额:
$ 50.13万 - 项目类别:
Inducible HMGB1 antagonist for viral-induced acute lung injury.
诱导型 HMGB1 拮抗剂,用于治疗病毒引起的急性肺损伤。
- 批准号:
10591804 - 财政年份:2023
- 资助金额:
$ 50.13万 - 项目类别:
MAP2K1 AND MAP2K2 IN ACUTE LUNG INJURY AND RESOLUTION
MAP2K1 和 MAP2K2 在急性肺损伤中的作用及缓解
- 批准号:
10741574 - 财政年份:2023
- 资助金额:
$ 50.13万 - 项目类别:
Development of a new treatment for COVID-19-related acute lung injury targeting the microbiota-derived peptide corisin
针对微生物群衍生肽 corisin 开发治疗 COVID-19 相关急性肺损伤的新疗法
- 批准号:
23K07651 - 财政年份:2023
- 资助金额:
$ 50.13万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Probing immunovascular mechanobiology in pneumonia-associated acute lung injury at the single capillary level
在单毛细血管水平探讨肺炎相关急性肺损伤的免疫血管力学生物学
- 批准号:
10679944 - 财政年份:2023
- 资助金额:
$ 50.13万 - 项目类别:
The amyloid precursor protein protects against acute lung injury
淀粉样前体蛋白可预防急性肺损伤
- 批准号:
10575258 - 财政年份:2023
- 资助金额:
$ 50.13万 - 项目类别:
Role of macrophages and miRNA in regulating lung macrophage polarization and lung pathogenesis during respiratory virus-induced acute lung injury in normal and diabetic Syrian hamsters.
正常和糖尿病叙利亚仓鼠呼吸道病毒引起的急性肺损伤期间巨噬细胞和 miRNA 在调节肺巨噬细胞极化和肺部发病机制中的作用。
- 批准号:
10701207 - 财政年份:2023
- 资助金额:
$ 50.13万 - 项目类别:
Roles of N-glycans on neutrophil beta2 integrins in progression of acute lung injury
N-聚糖对中性粒细胞β2整合素在急性肺损伤进展中的作用
- 批准号:
10837431 - 财政年份:2023
- 资助金额:
$ 50.13万 - 项目类别:














{{item.name}}会员




